Roswell Park Cancer Institute

Roswell park.jpg

Mikhail Blagosklonny

From Wikipedia, the free encyclopedia
Jump to navigationJump to search
Mikhail Blagosklonny
Alma materFirst Pavlov State Medical University of St. Peterburg
Scientific career
FieldsAnti-aging medicine, oncology
Institutions

Mikhail Blagosklonny is a scientist who studies cancer and aging. He is an adjunct faculty member at the Roswell Park Cancer Institute in Buffalo, New York.[1]

Career[edit]

Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[citation needed] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Cancer Institute.[2]

Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[3] Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.[4]

Rapamycin and aging[edit]

Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[5] He advocates for rapamycin use in longevity research.[6]

Editorial activities[edit]

Blagosklonny is editor-in-chief of Aging,[7] Cell Cycle,[8] and Oncotarget.[9] In addition, he is associate editor of Cancer Biology & Therapy[10] and a member of the editorial board of Cell Death & Differentiation.[11]

The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,[12] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[13] in July 2015.[12] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.[14]

References[edit]

  1. ^ Roswell Park website page on Blagosklonny
  2. ^ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute", Cancer Biology & Therapy, 8(9): 753–752, May 2009, 
  3. ^ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute". Cancer Biology & Therapy. 8(9): 753–752. May 2009. 
  4. ^ "Mikhail Blagosklonny". Roswell Park Comprehensive Cancer Center. Retrieved 2020-05-01.
  5. ^ Stipp, David (2011). "A New Path to Longevity". Scientific American. 306 (1): 32–39. doi:10.1038/scientificamerican0112-32. PMID 22279832.
  6. ^ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Retrieved November 20, 2016.
  7. ^ "Editorial Board". Aging. Retrieved 2016-11-20.
  8. ^ "Editorial Board". Cell Cycle. Taylor & Francis. Retrieved 2016-11-20.
  9. ^ "Editorial Board". Oncotarget. Retrieved 2016-11-20.
  10. ^ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20.
  11. ^ "About the journal". Cell Death & Differentiation. Retrieved 2016-11-20.
  12. ^ Jump up to:a b Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. Archived from the original on 20 April 2016. Retrieved 2016-11-20.
  13. ^ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. Archived from the original on 2 December 2016. Retrieved 19 April 2016.
  14. ^ "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. 6 December 2016. Archived from the original on 24 December 2016. Retrieved 17 January 2017.

When public refer to modern medicine, precision plays one of the most crucial roles and people’s lives are literally dependent on it. Likewise, any researches pertaining to medicine are required to comply with the top standards. The challenge today is that any results of researches can be posted online and used as a reference without being precisely checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and tried to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality measure. That helps both readers and authors to verify publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication.” Oncotarget website demonstrates a complete publications list with corresponding scores higher than 100 as well as reports mentioned previously. Mikhail (Misha) Blagosklonny glad to share his new approach and hopes it creates the required help to anyone, who has interest in oncology.
Blagosklonny
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was published back in 2018 by Oncotarget and written by various experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The paper has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are aiming to comprehend the very meaning of it. Based on the Altmetric website, the score relates to “how many people have been exposed to and engaged with a scholarly output.” Likewise, the article about melanoma, was used for citations in various news articles 69 times. Moreover, it was mentioned in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their news on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This research has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do get useful scientific facts. Oncotarget is glad to have the ability to share with online viewers this highly appreciated and high-quality information, that is trustworthy and reliable.
Misha Blagosklonny

Comments

  1. AnonymousDecember 22, 2022 at 10:30 PM

    Hey thanks for sharing this amazing content, We also have some amazing content to reduce workplace stress at Resiliency Program

    ReplyDelete

Post a Comment

Popular posts from this blog

Editor-in-Chief Oncotarget

Mikhail Blagosklonny Location  New York ,  New York ,  United States Regions  Greater New York Area ,  East Coast ,  Northeastern US Gender  Male Website  about.me/mikhailblagosklonny Facebook  View on Facebook LinkedIn  View on LinkedIn Twitter  View on Twitter Mikhail (Misha) V. Blagosklonny, MD, Ph.D. Professor of Oncology at Roswell Park Cancer Institute, Buffalo, NY, USA. His research interests range from molecular and cellular biology to clinical investigations and specifically include oncogenes and tumor suppressors, signal transduction, cell cycle, mitosis, apoptosis, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies such as exploiting cancer cell cycling and drug resistance for selective protection of normal cells. He has extended this approach to other age-related diseases and aging itself, thus revealing anti-aging drugs such as rapamycin to be used today (Cell Cycle, 200...
Read more

Professor of Oncology

Image
Mikhail Blagosklonny Professor of Oncology, RPCI and Editor-in-Chief, Oncotarget Verified email at oncotarget.com https://scholar.google.com/citations?user=REO9YogAAAAJ&hl=en Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 G Kroemer, L Galluzzi, P Vandenabeele, J Abrams, ES Alnemri, ... Cell death & differentiation 16 (1), 3-11 3039 2009 Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 L Galluzzi, I Vitale, JM Abrams, ES Alnemri, EH Baehrecke, ... Cell Death & Differentiation 19 (1), 107-120 2316 2012 Stabilization of wild-type p53 by hypoxia-inducible factor 1α WG An, M Kanekal, MC Simon, E Maltepe, MV Blagosklonny, LM Neckers Nature 392 (6674), 405-408 995 1998 Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 L Galluzzi, I Vitale, SA Aaronson, JM Abrams, D Adam, P Agostinis, ... Cell Death & Differentiation...
Read more

From rapalogs to anti-aging formula

Image
From rapalogs to anti-aging formula Mikhail V. Blagosklonny Go to: Abstract Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence. Rapamycin slows aging and extends life span in a variety of species from worm to mammals. Rapalogs can prevent age-related diseases, including cancer, atherosclerosis, obesity, neurodegeneration and retinopathy and potentially rejuvenate stem cells, immunity and metabolism. Here, I further suggest how rapamycin can be combined with metformin, inhibitors of angiotensin II signaling (Losartan, Lisinopril), statins (simvastatin, atorvastatin), propranolol, aspirin and a PDE5 inhibitor. Rational combinations of these drugs with physical exercise and an anti-aging diet (Koschei formula) can maximize their anti-aging effects and decrease side effects. Keywords:  lifespan, longevity, rejuvenation, health, diseases At first, the discovery of anti-aging p...
Read more